Financial Counselors Inc. Sells 384 Shares of Edwards Lifesciences Co. (NYSE:EW)

Financial Counselors Inc. cut its position in Edwards Lifesciences Co. (NYSE:EW) by 7.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,476 shares of the medical research company’s stock after selling 384 shares during the period. Financial Counselors Inc.’s holdings in Edwards Lifesciences were worth $295,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. First Community Trust NA acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $29,000. Webster Bank N. A. acquired a new position in shares of Edwards Lifesciences in the second quarter valued at approximately $39,000. Versant Capital Management Inc increased its position in shares of Edwards Lifesciences by 206.3% during the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after acquiring an additional 326 shares in the last quarter. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth $32,000. Finally, Avior Wealth Management LLC lifted its position in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on EW shares. Oppenheimer reiterated an “outperform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a report on Thursday, September 12th. Robert W. Baird dropped their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. UBS Group lowered their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a report on Tuesday, September 10th. Finally, Wells Fargo & Company reduced their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average target price of $76.85.

Edwards Lifesciences Price Performance

NYSE:EW opened at $71.35 on Friday. The company has a market cap of $42.08 billion, a P/E ratio of 10.30, a P/E/G ratio of 4.05 and a beta of 1.12. The firm’s fifty day moving average price is $68.10 and its two-hundred day moving average price is $75.15. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.59 EPS. Equities analysts expect that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,000 shares of company stock worth $2,657,000. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.